Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Equillium, Inc. - Common Stock (NQ:EQ)

0.4552 -0.0173 (-3.66%)
Streaming Delayed Price Updated: 3:47 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
From Equillium, Inc.
Via Business Wire
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
From Equillium, Inc.
Via Business Wire
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Stifel Healthcare Conference
From Equillium, Inc.
Via Business Wire
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium Inc.
Via Business Wire
Equillium Maintains Rights to Itolizumab Following Ono Partnership
From Equillium Inc.
Via Business Wire
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
From Equillium, Inc.
Via Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
From Equillium, Inc.
Via Business Wire
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
From Equillium Inc.
Via Business Wire
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
From Equillium, Inc.
Via Business Wire
Equillium to Participate in Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium to be included in the Russell Microcap® Index
From Equillium, Inc.
Via Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
From Equillium Inc.
Via Business Wire
Equillium to Present at the Jefferies Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
From Equillium Inc.
Via Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
From Equillium, Inc.
Via Business Wire
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
From Equillium, Inc.
Via Business Wire
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
From Equillium, Inc.
Via Business Wire
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
From Equillium, Inc.
Via Business Wire
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
From Equillium, Inc.
Via Business Wire
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
From Equillium, Inc.
Via Business Wire
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
From Equillium, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.